Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

BACKGROUND: Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance in clinical cohorts may point to strategies to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Waks, A. G., Cohen, O., Kochupurakkal, B., Kim, D., Dunn, C. E., Buendia, J. Buendia, Wander, S., Helvie, K., Lloyd, M. R., Marini, L., Hughes, M. E., Freeman, S. S., Ivy, S. P., Geradts, J., Isakoff, S., LoRusso, P., Adalsteinsson, V. A., Tolaney, S. M., Matulonis, U., Krop, I. E., D’Andrea, A. D., Winer, E. P., Lin, N. U., Shapiro, G. I., Wagle, N.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7946408/
https://ncbi.nlm.nih.gov/pubmed/32245699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.annonc.2020.02.008
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares